Your browser doesn't support javascript.
loading
Prevalence and epidemiological trends in mortality due to COVID-19 in Saudi Arabia.
Alissa, D A; Aburas, W; Almasuood, R; Almudaiheem, H Y; Al Aseri, Z; Alrabiah, F; Ezzat, H; Moulana, A A; Alawi, M M; Al-Mutairy, E; Alaama, T; Alamri, M S; Bamousa, M S; Alshehri, A A; Alosaimi, M H; Alali, A; Nori, R; Devol, E B; Mohamed, G; Al-Jedai, A H.
Afiliação
  • Alissa DA; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia; Colleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia.
  • Aburas W; University of Hail, College of Pharmacy, Hail, Saudi Arabia.
  • Almasuood R; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
  • Almudaiheem HY; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
  • Al Aseri Z; Department of Emergency Medicine and Critical Care, King Saud University, Riyadh, Saudi Arabia; Adult Critical Care, Ministry of Health, Riyadh, Saudi Arabia.
  • Alrabiah F; Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Ezzat H; Hematology Programs, Ministry of Health, Saudi Arabia; John Hopkins Aramco Healthcare, Dharan, Saudi Arabia; University of British Columbia, Canada.
  • Moulana AA; Forensic Medicine Center, Makkah Al Mukarramah, Saudi Arabia.
  • Alawi MM; Infection Control & Environmental Health Unit, Department of Medical Microbiology & Parasitology, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
  • Al-Mutairy E; Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Alaama T; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia; Colleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia.
  • Alamri MS; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
  • Bamousa MS; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia; Forensic Medicine General Directorate, Ministry of Health, Riyadh, Saudi Arabia.
  • Alshehri AA; Forensic Medicine Center, Ministry of Health, Riyadh, Saudi Arabia.
  • Alosaimi MH; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia; Mortality Affairs, Ministry of Health, Riyadh, Saudi Arabia.
  • Alali A; Internal Medicine and Infectious Diseases, King Saud Medical City, Riyadh, Saudi Arabia.
  • Nori R; Internal Medicine Department, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
  • Devol EB; Department of Biostatistics, Epidemiology & Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Mohamed G; Department of Biostatistics, Epidemiology & Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Al-Jedai AH; Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia; Colleges of Medicine and Pharmacy, Al-Faisal University, Riyadh, Saudi Arabia. Electronic address: ahaljedai@moh.gov.sa.
Public Health ; 215: 31-38, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36634404
ABSTRACT

OBJECTIVES:

This article describes the prevalence and epidemiological trends of COVID-19 mortality in the largest registry in the Kingdom of Saudi Arabia (KSA). STUDY

DESIGN:

A prospective epidemiological cohort study using data from all healthcare facilities in KSA collected between March 23, 2020, and April 30, 2022. Data on the number of daily deaths directly related to COVID-19 were gathered, analyzed, and reported.

METHOD:

Data analysis was carried out using national and regional crude case fatality rate and death per 100,000 population. Descriptive statistics using numbers and proportions were used to describe age, gender, nationality, and comorbidities. The mortality trend was plotted and compared with international figures. In addition, the most common comorbidities associated with mortality and the proportion of patients who received COVID-19 vaccine were reported.

RESULTS:

The total reported number of deaths between March 23, 2020, and April 30, 2022, was 9085. Crude case fatality rate was 1.21%, and death per 100,000 population was 25.38, which compared favorably to figures reported by several developed countries. The highest percentages of deaths were among individuals aged between 60 and 69 years, males (71%), and individuals with diabetes (60%). Only 2.8% of mortalities occur in patients who received COVID-19 vaccine. Diabetes, hypertension, and heart failure had the highest attributable risk of mortality among patients who died due to COVID-19.

CONCLUSION:

Case fatality rate and death per 100,000 population in KSA are among the lowest in the world due to multiple factors. Several comorbidities have been identified, namely, diabetes, hypertension, obesity, and cardiac arrhythmias.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus / COVID-19 / Hipertensão Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Public Health Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus / COVID-19 / Hipertensão Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Public Health Ano de publicação: 2023 Tipo de documento: Article